How long is a course of treatment with Evantumumab/Carestream?

Amivantamab is a bispecific antibody drug that mainly targets the EGFR and MET pathways and is used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. One of the questions that many patients and family members are most concerned about when starting medication is "how long is a course of treatment?" Judging from the currently disclosed dosage regimen, the course of treatment is not a single time period, but varies according to different combination regimens and treatment purposes.

If patients take evantumumab alone or in combination with lazertinib (Lazertinib), a more intensive dosing approach will be used in the initial phase. Dosing will occur once a week during the first five weeks of treatment, with the first dose split over two days to reduce the risk of infusion-related reactions. Beginning in the seventh week, dosing frequency was reduced to once every two weeks to ensure long-term drug exposure and therapeutic effect. For patients, this means that initial treatment requires more frequent visits to medical institutions, and as treatment progresses, the treatment gradually shifts to a more soothing maintenance phase.

Another common regimen is evantumumab combined with the chemotherapy drugs carboplatin and pemetrexed. Under this model, patients also receive intensive dosing in the initial phase, once a week for four weeks, with the dose divided into two doses during the first week. Starting from the seventh week, the dosing frequency is adjusted to once every three weeks, consistent with the conventional chemotherapy cycle. This design not only facilitates synchronization with chemotherapy, but also allows patients to have better compliance during long-term treatment.

As a targeted antibody, evantumumab treatment often continues until the disease is no longer controlled or the patient cannot tolerate it. In some overseas clinical practices, some patients have remained stable for a year or more after receiving this drug, but this does not mean that there is a uniform time limit for the course of treatment.

Reference materials:https://www.rybrevant.com/